Argos Therapeutics, Inc. is developing fully personalized immunotherapies that target unique features of a patient’s disease. This new generation of personalized therapeutics trains the immune system to recognize and attack diseases. Argos’ scientific leadership in RNA-loaded dendritic cells and advanced manufacturing processes provide a platform that we believe can tackle a wide range of cancers and infectious diseases.
Argos Announces Issuance of Arcelis(R) Technology Platform Patent
Argos Therapeutics to Present at the Rodman & Renshaw 16th Annual Global Investment Conference
Argos Therapeutics Reports Second Quarter 2014 Financial Results and Operational Highlights